AFLIBERCEPT

Information current as at: 1 July 2026

PBAC meeting date: November 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Eylea®
Form and strength:: Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL)

Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL) pre-filled syringe
Submission sponsor:: BAYER AUSTRALIA LTD
Condition/indication: (therapeutic use): Branch retinal vein occlusion (BRVO) with macular oedema Central retinal vein occlusion (CRVO) with macular oedema
Listing requested:: To request listing of the 8 mg strength of Eylea (originator brand of aflibercept) for the treatment of visual impairment due to macular oedema secondary to BRVO or CRVO.
Funding program:: PBS General Schedule
Request authority level:: Authority Required (Written) for initial treatment Authority Required (STREAMLINED) for continuing treatment
PBAC Submission type:: Change to existing listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: November 2026 PBAC meeting
2Opportunity for consumer comment:: Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a1262

Page last updated

23 July 2026

v.9.19